Business Context and Reporting Period
Company: Amarin Corporation plc (Nasdaq: AMRN)
Reporting Period: Fiscal Year Ended December 31, 2005
Business Model: Amarin is a neuroscience company focused on the research, development, and commercialization of novel drugs for central nervous system (CNS) disorders. Following the divestiture of its US sales and marketing operations (Amarin Pharmaceuticals Inc.) in February 2004 and the acquisition of Laxdale Limited (renamed Amarin Neuroscience Limited) in October 2004, the company has no marketable products and relies on equity financing and licensing fees.
Key Financial Metrics (Year Ended Dec 31, 2005)
| Metric | 2005 (UK GAAP) | 2005 (US GAAP) | 2004 (UK GAAP) |
|---|---|---|---|
| Net Sales Revenue | $0.5 million | $0 | $1.0 million (Discontinued) |
| Operating Loss | $(18.9) million | $(19.5) million | $(11.1) million |
| Net Loss | $(18.7) million | $(19.6) million | $4.0 million (Income) |
| Loss Per Share (Basic) | $(0.40) | $(0.42) | $0.21 |
| Cash and Cash Equivalents | $33.9 million | $33.9 million | $11.0 million |
| Debt | $0 | $0 | $2.0 million |
| Shareholders' Equity | $38.6 million | $(12.7) million | $16.7 million |
Note: 2004 results included significant gains from discontinued operations and debt settlements. 2005 results reflect continuing operations only.
Material Changes vs. Prior Period
- Revenue Shift: Revenue dropped to $0.5 million in 2005, derived solely from a licensing fee for MCT-125 (Multiple Sclerosis). In 2004, revenue of $1.0 million was entirely from discontinued operations (API sales prior to divestiture).
- Operating Expenses: Operating expenses increased to $19.4 million in 2005 from $9.9 million in 2004. This increase is primarily due to the full-year inclusion of Amarin Neuroscience Limited's expenses ($6.8 million) and the commencement of two Phase III clinical trials for Miraxion in Huntington's disease.
- Profitability: The company returned to a net loss position in 2005 ($18.7 million) compared to a net income of $4.0 million in 2004. The 2004 income was driven by a $24.6 million gain on the settlement of debt obligations to Elan and a $13.1 million gain on the disposal of Swedish operations, both classified as discontinued.
- Liquidity: Cash balances increased significantly from $11.0 million to $33.9 million, driven by two major equity financings in 2005 (May and December) raising approximately $44.5 million in gross proceeds.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Cash Runway: Management forecasts sufficient cash to fund operations into the fourth quarter of 2007.
- Development Milestones: The company aims to file a New Drug Application (NDA) for Miraxion in Huntington's disease in the first half of 2007. Phase III trials in the US and EU are ongoing.
- Partnerships: Amarin is seeking a development and marketing partner for Miraxion in depressive disorders in 2006.
Key Risks and Contingencies:
- Regulatory Approval: Success is heavily dependent on FDA and EMEA approval of Miraxion. Initial Phase III data showed statistical significance only in a specific genetic subgroup (CAG repeat length <= 44), representing ~70% of the patient population.
- Capital Requirements: The company has no marketable products and must raise additional capital to fund clinical trials and operations. Failure to secure funding could threaten the going concern status.
- Future Investment Rights: Investors in the May 2005 offering hold a "future investment right" to purchase up to $4.18 million of equity at a price of $1.75 per share if certain funding thresholds are not met by March 2006.
- Legal Proceedings: Pending litigation regarding Permax (compulsive gambling) remains, though the company considers the risk of significant liability remote. Five lawsuits regarding cardiac valvulopathy were settled in 2005.
Investor Verification Checklist
- Cash Burn Rate: Verify the accuracy of the $33.9 million cash balance and the projected runway to Q4 2007 given the high cost of Phase III trials.
- Future Investment Right: Confirm the status of the $4.18 million future investment right obligation and the potential dilution impact (approx. 2.4 million shares) if triggered in March 2006.
- Phase III Trial Design: Review the FDA Special Protocol Assessment (SPA) agreement and the specific inclusion criteria for the ongoing Huntington's disease trials to ensure the genetic subgroup focus is maintained.
- US GAAP vs. UK GAAP: Note the significant difference in Shareholders' Equity ($38.6M UK GAAP vs. $(12.7M) US GAAP) due to the treatment of intangible assets (Miraxion) and acquisition accounting (negative goodwill).
- Related Party Transactions: Review the consultancy agreement with Dalriada Limited (beneficiaries include Chairman Thomas Lynch) and the relationship with Icon plc (controlled by Director Dr. John Climax).